




Contents lists available at SciVerse ScienceDirect

Neurobiology of Disease

journal homepage: www.elsevier.com/locate/ynbdi

Metabotropic glutamate receptor-dependent long-term depression is impaired due to elevated ERK signaling in the Δ RG mouse model of tuberous sclerosis complex

Itzamarié Chévere-Torres^a, Hanoch Kaphzan^a, Aditi Bhattacharya^a, Areum Kang^a, Jordan M. Maki^a, Michael J. Gambello^b, Jack L. Arbiser^c, Emanuela Santini^a, Eric Klann^{a,*}

^a Center for Neural Science, New York University, New York, NY 10003, USA

^b Division of Medical Genetics, Department of Pediatrics, University of Texas Health Science Center at Houston, Houston, TX 77030, USA

^c Department of Dermatology, Emory University School of Medicine, Atlanta, GA 30322, USA

ARTICLE INFO

Article history:

Received 29 June 2011

Revised 8 November 2011

Accepted 8 December 2011

Available online xxxx

Keywords:

Tuberous sclerosis complex

TSC2

TSC1

mTORC1

ERK

Fragile X syndrome

mGluR-LTD

NMDAR-LTD

ABSTRACT

Tuberous sclerosis complex (TSC) and fragile X syndrome (FXS) are caused by mutations in negative regulators of translation. FXS model mice exhibit enhanced metabotropic glutamate receptor-dependent long-term depression (mGluR-LTD). Therefore, we hypothesized that a mouse model of TSC, Δ RG transgenic mice, also would exhibit enhanced mGluR-LTD. We measured the impact of TSC2-GAP mutations on the mTORC1 and ERK signaling pathways and protein synthesis-dependent hippocampal synaptic plasticity in Δ RG transgenic mice. These mice express a dominant/negative TSC2 that binds to TSC1, but has a deletion and substitution mutation in its GAP-domain, resulting in inactivation of the complex. Consistent with previous studies of several other lines of TSC model mice, we observed elevated S6 phosphorylation in the brains of Δ RG mice, suggesting upregulated translation. Surprisingly, mGluR-LTD was not enhanced, but rather was impaired in the Δ RG transgenic mice, indicating that TSC and FXS have divergent synaptic plasticity phenotypes. Similar to patients with TSC, the Δ RG transgenic mice exhibit elevated ERK signaling. Moreover, the mGluR-LTD impairment displayed by the Δ RG transgenic mice was rescued with the MEK-ERK inhibitor U0126. Our results suggest that the mGluR-LTD impairment observed in Δ RG mice involves aberrant TSC1/2-ERK signaling.

© 2011 Published by Elsevier Inc.

Introduction

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder that can cause hamartomas, benign and malignant neoplasms, seizures, mental impairment and autism (DiMario, 2004). At the molecular level, TSC is caused by either the loss or malfunction of either hamartin (TSC1) or tuberlin (TSC2), which interact in a heterodimer known as the TSC1/TSC2 complex, to negatively regulate mammalian target of rapamycin complex 1 (mTORC1) (Cheadle et al., 2000). mTORC1 functions as a molecular gatekeeper for cap-dependent translation initiation in neurons. Activation of the phosphoinositide 3-kinase (PI3K)/Akt and extracellular signal-regulated kinase (ERK) signaling pathways results in the phosphorylation of TSC2 and inhibition of the GTPase-activating protein (GAP) activity of TSC2, which leads to increased levels of Rheb-GTP. This type of signaling activates

the mTOR complex 1 (mTORC1) and subsequent phosphorylation of ribosomal S6 kinase 1 (S6K1) and eukaryote initiation factor 4E-binding protein (4E-BP), key translation initiation regulators (Cai et al., 2006; Jozwiak, 2006; Jozwiak et al., 2005; Orlova and Crino, 2010; Yang et al., 2006).

It has been estimated that sporadic cases of TSC range from 60 to 70% of the cases reported, and that TSC1 mutations are significantly underrepresented compared to TSC2 (Jones et al., 1997). TSC2 gene mutations are more frequent and result in a more severe phenotype in TSC patients (i.e. seizures and learning disability), with the exception of reported cases of patients with no mutation identified, as well as one TSC2 mutation that causes a more mild phenotype (Camposano et al., 2009; Dabora et al., 2001; Jansen et al., 2006; Kwiakowski, 2003). In addition, the TSC2 gene is more prone than the TSC1 gene to large deletions, rearrangements, and missense mutations. Of particular interest is the finding that missense mutations are clustered within TSC2 exons 34–38, which encode for either Rap1GAP or GAP3 (Maheshwar et al., 1997). The TSC2-GAP domain is an essential structural domain for the hydrolysis of GTP-bound Rheb to its inactive GDP-bound form (Tee et al., 2003).

Studies have shown that either loss or malfunction of TSC1 and TSC2 usually results in activation of S6K1 and enhanced ribosomal protein S6 phosphorylation, resulting in defective regulation of cell size and proliferation (Krymskaya, 2003; Uhlmann et al., 2004).

Abbreviations: 4E-BP, eIF4E binding protein; ACSF, artificial cerebrospinal fluid; CMV, cytomegalovirus; FXS, fragile X syndrome; GAP, GTPase-activating protein; GDP, guanosine diphosphate; GTP, guanosine triphosphate; mTORC1, mammalian target of rapamycin complex 1; Rheb, Ras homolog-enriched in brain; STEP, striatal-enriched tyrosine phosphatase; TSC, tuberous sclerosis complex.

* Corresponding author at: Center for Neural Science, New York University, 4 Washington Place, Room 809, New York, NY 10003, USA. Fax: +1 212 995 4011.

E-mail address: eklann@cns.nyu.edu (E. Klann).

Available online on ScienceDirect (www.sciencedirect.com).

Moreover, studies in hippocampal pyramidal neurons have shown that the TSC pathway regulates soma size, the density and size of dendritic spines, and the properties of excitatory synapses, particularly AMPA receptor-mediated currents (Tavazoie et al., 2005). Additional studies have shown that loss of TSC1 function in the brain leads to neocortical hyperexcitability associated with increased glutamate-mediated excitation in both human tissue and mouse brain (Wang et al., 2007). Finally, TSC2 heterozygous knockout mice were shown to exhibit elevated hippocampal mTORC1 signaling, which led to abnormal long-term potentiation (LTP) and deficits in hippocampus-dependent memory (Ehninger et al., 2008).

The Δ RG transgenic mouse has been developed, carrying a deletion in TSC2 of amino acid residues 1617–1655 and a substitution of amino acid residues 1679–1742, which interferes with both the GAP domain and rabaptin-5 binding motif of TSC2, respectively (Govindarajan et al., 2005; Pasumarthi et al., 2000). As a result, this dominant/negative TSC2 protein is not able to hydrolyze GTP-bound small G-proteins, such as Rap1 and Rheb (Govindarajan et al., 2005; Pasumarthi et al., 2000; Zhang et al., 2003). Previous studies have shown that Δ RG transgenic mice have increased expression of the dominant/negative TSC2 driven by the cytomegalovirus (CMV) promoter and develop skin and brain abnormalities consistent with those observed in TSC patients (Bhatia et al., 2009; Govindarajan et al., 2005; Sambucetti et al., 1989). In addition, behavioral studies on Δ RG mice have revealed increased anxiety levels and mild deficits in hippocampus-dependent learning and memory, consistent with TSC-related neuropsychiatric symptoms (Chévere-Torres et al., in press; Ehninger and Silva, 2010).

Fragile X syndrome (FXS) is caused by loss of function mutations in the RNA-binding protein, fragile X mental retardation protein (FMRP), whose normal function is to suppress translation (Ronesi and Huber, 2008). Consistent with this notion, mouse models of FXS display increased protein synthesis, enhanced mTORC1 signaling, and exaggerated metabotropic glutamate receptor-dependent long-term depression (mGluR-LTD) (Hou et al., 2006; Huber et al., 2002; Osterweil et al., 2010; Sharma et al., 2010). Based on evidence that both TSC1/2 and FMRP proteins act as negative regulators of protein synthesis and mTORC1 signaling, and the evidence that patients with TSC and FXS can both display autism spectrum disorder, we hypothesized that the mutations in TSC2-GAP domain in Δ RG mice would result in similar synaptic plasticity alterations and mTORC1 dysregulation as observed in other mouse models of TSC and FXS model mice. Herein we describe experiments with the Δ RG transgenic mice that were conducted to determine whether they exhibit hippocampal synaptic plasticity phenotypes consistent with other mouse models of TSC and FXS.

Materials and methods

Animals

Δ RG transgenic mice

Generation of Δ RG mice has been described previously (Govindarajan et al., 2005). Mouse genotyping was performed by PCR using transgene- and wild-type-specific primer sets.




Fig. 1. Overexpression of Δ RG TSC2 protein in mouse hippocampus. (A) Schematic representation of the dominant negative TSC2 Δ RG in mice that model tuberous sclerosis. (B) PCR identification of Δ RG transgene showed a corresponding band at 280 bp. The wild-type band is detected at 500 bp. (C) Hippocampal morphology in Δ RG mice. Nissl staining of sagittal sections showed no obvious aberrant morphology. (D) Immunolocalization of TSC2 in the mouse hippocampus. Increased levels of TSC2 were observed in hippocampal areas CA1 and CA3, and the dentate gyrus (DG) of Δ RG mice compared to WT mice.

Tsc1 floxed mice

Mice with floxed *Tsc1* (mixed genetic background composed of C57Bl/6J, 129/SvJae, BALB/cJ) were generated as described previously (Kwiatkowski et al., 2002). For the generation of experimental mice, we crossed heterozygous floxed *Tsc1* ($TSC1^{+/-}$) male mice and heterozygous floxed *Tsc1* ($TSC1^{+/-}$)- α CaMKII-Cre females. Mice were genotyped using Cre-specific primers and primers that identify floxed alleles of the *Tsc1* locus. The wild-type mice used in this study were $TSC1^{+/+}$ - α CaMKII-Cre and the experimental conditional heterozygous mice used in this study were $TSC1^{+/-}$ - α CaMKII-Cre (referred to as $TSC1^{+/-}$ cKO) mice.

Tsc2 floxed mice

Mice with floxed *Tsc2* (mixed genetic background composed of C57Bl/6J, 129/SvJae) were generated as described previously (Hernandez et al., 2007). For the generation of experimental mice, we crossed heterozygous floxed *Tsc2* ($TSC2^{+/-}$) male mice and heterozygous floxed *Tsc2* ($TSC2^{+/-}$)- α CaMKII-Cre females. Mice were genotyped using Cre-specific primers and primers that identify floxed alleles of the *Tsc2* locus. The wild-type mice used in this study were $TSC2^{+/+}$ - α CaMKII-Cre and the experimental conditional homozygous mice used in this study were $TSC2^{cKO/cKO}$ - α CaMKII-Cre (referred to as $TSC2^{-/-}$ cKO) mice.

For all experiments, male age-matched littermates were used. For biochemical experiments, 4–12 week-old mice were used, for LTP experiments 8–12 week-old mice were used, and 4–6 week-old mice were used for mGluR-LTD experiments. Mice were kept on a 12 h on-off light/dark cycle. Food and water were available at all times. All procedures were approved by the New York University Animal Care and Use Committee and followed the NIH Guidelines for the use of animals in research.

Western blot analysis

Protein extracts were prepared by homogenizing hippocampal tissue in ice-cold hypotonic lysis buffer (HLB) containing phosphatase and protease inhibitor mixtures. Homogenates (20 μ g) were resolved via 4–12% SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes. Immunoblotting was performed using standard techniques. Rabbit polyclonal antibodies were used to detect phospho-S6 (S235/236), phospho-S6 (S240/244), total S6, phospho-S6K1 (T389), and total S6K1 at a 1:1000 dilution (Cell Signaling Technologies, Beverly, MA). 1:1000 rabbit anti-phospho-S6K1 (T389, Millipore Corp., Billerica, MA). A monoclonal antibody was used to detect TSC1 levels at a 1:1000 dilution (Cell Signaling, Beverly, MA) in 5% BSA blocking solution. TSC2 levels were detected using a monoclonal antibody (CellSignaling, Beverly, MA) at a 1:1000 dilution in 5% BSA blocking solution. The dilution used for phospho-4E-BP (T37/46) and total 4E-BP antibodies was 1:500 (Cell Signaling Technologies, Beverly, MA) in 5% BSA/I-Block. Phospho-ERK (T202/404) and total ERK antibodies were diluted at 1:2000. β -actin and α -tubulin antibodies (Sigma-Aldrich, St. Louis, MO) were diluted 1:10,000 in 5% milk/TBS. Anti-rabbit and anti-mouse HRP-tagged antibodies (Promega, Madison, WI) were diluted 1:5000 in 0.2% I-Block (Tropix, Foster City, CA) and 1:10,000 in 5% milk/TBS, respectively. Blots were developed using enhanced chemiluminescence detection (GE Healthcare, Fairfield, CT).

Immunohistochemistry and histology

Sagittal sections (40 μ m thick) were blocked with 1% BSA and incubated overnight at 4 $^{\circ}$ C with TSC2 rabbit monoclonal antibody (1:200; Epitomics, Burlingame, CA) in 1% BSA. Sections were washed with PBS and incubated with secondary antibody for 30 min. Sections then were incubated with ABC reagent (Pierce, Rockford, IL) and immunostaining was visualized using the VIP substrate kit for

peroxidase (Vector Laboratories, Burlingame, CA). Brains from a different set of mice were used for histological studies. Sagittal sections (40 μ m thick) were mounted onto subbed slides. Nissl staining was performed according to standard procedures. Sections from immunohistochemistry and Nissl staining were viewed and photographed using a BX51 Olympus microscope (Olympus, UK) and Neurolucida 7 software (MBF Bioscience, Williston, VT).

Electrophysiology

Brains from age-matched littermate mice were removed and transverse hippocampal slices (400 μ m) were prepared. Hippocampal slices were placed in cold-cutting solution (in mM: 110 sucrose, 60 NaCl, 3 KCl, 1.25 NaH_2PO_4 , 28 NaHCO_3 , 5 D-glucose, 0.6 ascorbic acid, 0.5 CaCl_2 , and 7 MgCl_2 , gassed with 95% O_2 /5% CO_2). The slices were incubated with a 50:50 cutting/artificial CSF (ACSF) solution (in mM: 125 NaCl, 2.5 KCl, 1.25 NaH_2PO_4 , 25 NaHCO_3 , 25 D-glucose, 210




Fig. 2. ARG mice have normal basal synaptic transmission and paired-pulse facilitation. (A) Input/output plot indicates that both wild-type (WT) and ARG mice had comparable fEPSP slopes with increasing stimulation intensities, indicating normal postsynaptic function (WT, $n = 16$; ARG, $n = 13$; 2–3 slices/mouse per genotype, $p < 0.05$, ANOVA). (B) Input/output plot indicates that both wild-type (WT) and ARG mice had comparable fiber volley amplitude with increasing stimulation intensities, indicating normal presynaptic function (WT, $n = 14$; ARG, $n = 17$; 2–3 slices/mouse per genotype, $p < 0.05$, ANOVA). (C) ARG mice exhibit normal paired-pulse facilitation (PPF) compared to their WT littermates using interpulse intervals ranging from 10 to 300 ms. The percent of facilitation was calculated from the ratio of the second fEPSP to the first fEPSP (WT, $n = 8$; ARG, $n = 8$; 2–3 slices/mouse per genotype, $p < 0.05$, ANOVA).

2 CaCl₂, and 1MgCl₂) for 15 min, followed by equilibration for 1 h in a humid, oxygenated interface chamber continuously perfused with 32 °C ACSF at a rate of 2 ml/min. Field excitatory postsynaptic potentials (fEPSPs) were evoked by stimulation of the Schaeffer collateral pathway and recorded in stratum radiatum of area CA1 using a glass recording pipette (1–4 MΩ). Stimulus intensity was adjusted to elicit a fEPSP that was 50% of the maximum response in each slice. Baseline measurements were taken for 30 min prior to delivery of a single train of high-frequency stimulation (HFS; 100 Hz for 1 s) to induce early phase LTP (E-LTP), prior to delivery of four, spaced trains of HFS (100 Hz for 1 s, 5 min intertrain interval) to induce late phase LTP (L-LTP), for 20 min prior to treatment with DHPG (50 μM, 10 min; Ascent, Princeton, NJ) to induce mGluR-LTD, or for 20 min prior to deliver 900 pulses of low-frequency stimulation (LFS; 1 Hz, 15 min)

to induce N-methyl D-aspartate NMDA-LTD. When indicated, ACSF was supplemented with U0126 (1 mM, Promega, Madison, WI). For LTD rescue experiments, baseline measurements were taken for 30 min prior to application of DHPG (50 μM, 10 min) in the presence of U0126 (1 μM). Afterward, fEPSPs were evoked and recorded in the stratum radiatum of area CA1 in the presence of the inhibitor for 1 h.

Statistical analysis

GraphPad Prism data analysis software (San Diego, CA) was used for graph production and statistical analysis was used to assess the data. Student's *t*-tests and two-way ANOVAs were used for biochemical and electrophysiological data analysis, respectively. Data represent mean ± SEM, with *p* < 0.05 used as significance criteria.




Fig. 3. Δ RG mice have normal hippocampal E-LTP, L-LTP and NMDAR-LTD but have impaired mGluR-LTD. (A) Top, representative fEPSPs in slices from wild-type (WT) and Δ RG mice before and after receiving one train of HFS. Calibration: 5 mV, 5 ms. Bottom, a single train of HFS elicits similar levels of E-LTP in WT and Δ RG mice (WT, *n* = 7; Δ RG, *n* = 7; 2–3 slices/mouse per genotype. *p* > 0.05, ANOVA). (B) Top, representative fEPSPs in slices from WT and Δ RG mice before and after receiving four trains of HFS. Bottom, four trains of HFS elicited similar levels of L-LTP in WT and Δ RG mice (WT, *n* = 10; Δ RG, *n* = 15; 2–3 slices/mouse per genotype. *p* > 0.05, ANOVA). (C) Top, representative fEPSPs in slices from WT and Δ RG mice before and after treatment with DHPG (50 μM, 10 min) to induce mGluR-LTD. Bottom, DHPG application induced LTD in WT mice, but not in Δ RG mice (WT, *n* = 7; Δ RG, *n* = 8; 2–3 slices/mouse per genotype. ***p* < 0.01, ANOVA). (D) Top, representative fEPSPs in slices from wild-type (WT) and Δ RG mice before and after receiving 900 pulses of LFS for 15 min. Bottom, LFS elicits similar levels of NMDAR-LTD in WT and Δ RG mice (WT, *n* = 12; Δ RG, *n* = 12; 3 slices/mouse per genotype. *p* > 0.05, ANOVA).

Results

ΔRG mice exhibit normal hippocampal LTP but impaired mGluR-dependent LTD

First, we confirmed the presence of the ΔRG transgene (Fig. 1A) by PCR techniques, detecting a band of 280 bp (Fig. 1B). We determined whether the loss of TSC2-GAP function in ΔRG mice resulted in aberrant hippocampal morphological changes. Nissl staining of sections from ΔRG mice indicated they have normal gross hippocampal morphology (Fig. 1C). To determine whether TSC2 levels were increased, we examined hippocampal tissue from ΔRG mice and their wild-type littermates with immunocytochemistry and observed increased TSC2 levels in ΔRG mice compared to their wild-type controls (Fig. 1D), consistent with previous studies (Bhatia et al., 2009).

Because mice with mutations in negative modulators of translation exhibit altered synaptic function (Richter and Klann, 2009), we examined several forms of hippocampal synaptic plasticity in slices from ΔRG mice. Analysis of synaptic output in response to increasing stimulatory input indicated that the basal synaptic transmission was normal in hippocampal area CA1 of the ΔRG mice (Fig. 2A). Fiber volley amplitude measured with increasing stimulation also was unaltered in ΔRG mice (Fig. 2B). We next examined paired-pulse facilitation (PPF), a short-lasting form of presynaptic plasticity evoked by temporally linked stimuli, and found that PPF was unaltered in ΔRG mice using both short and long interpulse intervals (Fig. 2C). We proceeded to determine whether the ΔRG mice exhibited altered long-term potentiation (LTP). We used a single train of high-frequency stimulation (HFS) to induce early phase LTP (E-LTP) and four, spaced trains of HFS to induce protein synthesis-dependent late phase LTP (L-LTP) in hippocampal slices from wild-type and ΔRG mice. We observed that both E-LTP and L-LTP in ΔRG mice were indistinguishable from that in their wild-type littermates (Figs. 3A and B). Thus, basal synaptic transmission, PPF, E-LTP, and L-LTP are unaltered in ΔRG mice.

Previous studies have shown that a mouse model of fragile X syndrome (FXS) exhibits enhanced hippocampal mGluR-LTD due to improper regulation of translation and its uncoupling from mGluR signaling (Osterweil et al., 2010; Ronesi and Huber, 2008; Sharma et al., 2010). In addition, clinical studies have shown increased immunoreactivity for group I mGluRs (mGluR1/5) and phosphorylated ribosomal protein S6 within cortical tubers and subependymal giant-cell tumors of TSC specimens (Boer et al., 2008), suggesting upregulation of mGluR-mTORC1 signaling similar to that observed in FXS model mice (Sharma et al., 2010). Therefore, we hypothesized that hippocampal mGluR-dependent LTD would be enhanced in the ΔRG mice. Hippocampal slices from ΔRG mice and their wild-type littermates were treated with DHPG (50 μM , 10 min), a selective agonist of group I mGluRs, which resulted in a pronounced initial depression of synaptic transmission in both ΔRG and wild-type mice (Fig. 3C). This depression rapidly returned to near baseline levels in ΔRG mice after drug washout, whereas in wild-type mice it was followed by a robust long-lasting depression (Fig. 3C). This finding indicates that mutations affecting the TSC2-GAP domain result in an impairment of mGluR-LTD in the hippocampus. To determine the receptor specificity of the LTD deficit in ΔRG mice, low-frequency stimulation (LFS) was utilized to induce N-methyl D-aspartate receptor-dependent LTD (NMDAR-LTD) in hippocampal slices from ΔRG mice and their wild-type littermates. We observed that NMDAR-LTD in ΔRG mice was identical to that of their wild-type littermates (Fig. 3D). These findings indicate that the impaired LTD is specific to altered mGluR-dependent signaling in the ΔRG mice.

We next tested whether mGluR-LTD also was impaired in mice with a heterozygous conditional deletion of *Tsc1* ($Tsc1^{+/-}$ cKO) and homozygous conditional deletion of *Tsc2* ($Tsc2^{-/-}$ cKO) in postnatal forebrain neurons under the control of the $\alpha CaMKII$ promoter

($\alpha CaMKII-Cre$) (Supplementary Fig. 1). We found that both $Tsc1^{+/-}$ cKO and $Tsc2^{-/-}$ cKO mice exhibited significant impairments in mGluR-LTD compared to their wild-type controls (Figs. 4A and B). Further analysis and comparison of the average fEPSP slopes from ΔRG , $Tsc1^{+/-}$ cKO and $Tsc2^{-/-}$ cKO hippocampal slices during the time period of 20 to 50 min after DHPG application revealed that all three TSC mouse models have a similar level of LTD impairment (Fig. 4C). These findings indicate that disruption of the TSC1/2 complex either by conditional deletion of *Tsc1/2* genes or by mutations affecting the TSC2-GAP domain results in deficient mGluR-LTD expression in the hippocampus.




Fig. 4. mGluR-LTD is impaired in mice with conditional deletions of TSC1 and TSC2. (A) Top, representative fEPSPs in slices from WT and $Tsc1^{+/-}$ cKO mice before and after treatment with DHPG (50 μM , 10 min) to induce mGluR-LTD. Calibration: 5 mV, 5 ms. Bottom, DHPG application induced LTD in WT mice and impaired LTD in $Tsc1^{+/-}$ cKO (WT, $n=8$; $Tsc1^{+/-}$ cKO, $n=8$; 2–3 slices/mouse per genotype. * $p<0.05$, ANOVA). (B) Top, representative fEPSPs in slices from WT and $Tsc2^{-/-}$ cKO mice before and after treatment with DHPG (50 μM , 10 min) to induce mGluR-LTD. Bottom, DHPG application induced LTD in WT mice and impaired LTD in $Tsc2^{-/-}$ cKO (WT, $n=8$; $Tsc2^{-/-}$ cKO, $n=4$; 1–2 slices/mouse per genotype. * $p<0.05$, ANOVA). (C) Bar graph depicting average fEPSP slope 20 to 50 min after the washout of DHPG. DHPG application induced same level of mGluR-LTD in ΔRG , $Tsc1^{+/-}$ cKO, and $Tsc2^{-/-}$ cKO mice (ΔRG , $n=8$; $Tsc1^{+/-}$ cKO, $n=8$; $Tsc2^{-/-}$ cKO, $n=4$. $p>0.05$, Student's *t*-test compared with ΔRG for the given time period).

Hippocampal mTORC1 signaling in Δ RG mice

The impairment in mGluR-LTD led us to examine mTORC1 signaling in hippocampal homogenates from the Δ RG mice. Western blot analysis indicated that although phosphorylation of serine 235/236 on ribosomal protein S6 was elevated in the Δ RG mice, phosphorylation of serine 240/244, a rapamycin-sensitive/mTORC1-dependent site, was unaffected (Fig. 5A). Moreover, phosphorylation of eukaryotic initiation factor 4E-binding protein (4E-BP) and p70 S6 kinase 1 (S6K1), direct substrates of mTORC1, were not altered in the Δ RG mice (Fig. 5B). Because phosphorylation of serine 235/236 on S6 can be regulated by both mTORC1 and ERK signaling (Pende et al., 2004; Roux et al., 2004), we examined ERK1/2 phosphorylation in the hippocampus of Δ RG mice. We observed that the Δ RG mice exhibited a robust increase in ERK1/2 phosphorylation compared to their wild-type littermates (Fig. 5C). These findings suggest that the impaired mGluR-LTD observed in Δ RG mice is not a direct consequence of elevated mTORC1 signaling as initially postulated, but could be related to aberrant TSC1/2-ERK signaling.




We also examined ERK1/2 phosphorylation in the hippocampus of TSC1^{+/-} cKO and TSC2^{-/-} cKO mice to determine whether enhanced ERK signaling also is a feature of TSC1/2 deletion in the brain. We found that ERK phosphorylation was not affected in the hippocampus

of either TSC1^{+/-} cKO or TSC2^{-/-} cKO mice (Figs. 6A and B). These data suggest that a distinct molecular mechanism may be responsible for the deficit observed in mGluR-LTD in TSC1^{+/-} cKO and TSC2^{-/-} cKO mice, while the mGluR-LTD impairment and aberrant ERK1/2 activation observed in Δ RG mice is because of TSC2-GAP mutations in Δ RG mice.




Inhibition of MEK-ERK signaling rescues mGluR dependent-LTD in Δ RG mice

Our findings of enhanced ERK phosphorylation led us to examine the contribution of MEK-ERK signaling to the impaired mGluR-LTD exhibited by the Δ RG mice. In wild-type mice, mGluR-LTD requires activation of both mTORC1 and MEK-ERK signaling (Banko et al., 2006; Gallagher et al., 2004; Hou and Klann, 2004; Sharma et al., 2010). We utilized the MEK inhibitor U0126 (Favata et al., 1998) and performed dose/response experiments in hippocampal slices from wild-type mice in an attempt to find an effective dose at which levels of ERK phosphorylation were reduced but not completely blocked and did not compromise the integrity of mGluR-LTD induction in wild-type mice (Fig. 7A). Western blot analysis indicated that ERK phosphorylation was significantly reduced when slices were incubated with U0126 at concentrations of either 1 μ M (approximately

A



B



C





Fig. 5. mTORC1 signaling is unaltered, but S6 and ERK phosphorylation are elevated in the hippocampus of Δ RG mice. (A) S6 phosphorylation at serine 235/236 is increased, whereas phosphorylation at serine 240/244 is not altered in the hippocampus of Δ RG mice (WT, $n = 3$; Δ RG $n = 4$. * $p < 0.05$, Student's t -test). (B) Phosphorylation of 4E-BP (WT, $n = 3$; Δ RG $n = 3$, $p > 0.05$, Student's t -test) and S6K1 are unaltered (WT, $n = 4$; Δ RG $n = 6$, $p > 0.05$, Student's t -test) in Δ RG mice. (C) ERK1/2 phosphorylation is increased in Δ RG mice (WT, $n = 3$; Δ RG $n = 3$. * $p < 0.05$, Student's t -test). Phospho-protein phosphorylation immunoreactivity was normalized to tubulin and its corresponding total protein immunoreactivity.




Fig. 6. ERK signaling is unaltered in the hippocampus of TSC1^{+/-} cKO and TSC2^{-/-} cKO mice. (A) Basal ERK1/2 phosphorylation is normal in TSC1^{+/-} cKO mice (WT, n = 3; TSC1^{+/-} cKO, n = 3). $p > 0.05$, Student's *t*-test). (B) Basal ERK1/2 phosphorylation is normal in TSC2^{-/-} cKO mice (WT, n = 3; TSC2^{-/-} cKO, n = 3). $p > 0.05$, Student's *t*-test). ERK1/2 phosphorylation immunoreactivity was normalized to tubulin and total ERK1/2 immunoreactivity.

30% inhibition) or 5 μ M (approximately 80% inhibition), but not at 100 nM (Fig. 7A). To determine whether the elevated MEK–ERK signaling was involved in the impaired mGluR-LTD, hippocampal slices from Δ RG mice and their wild-type littermates were treated with DHPG in the presence of U0126 (1 μ M). Treatment with U0126 rescued the mGluR-LTD deficit observed in hippocampal slices from Δ RG mice (Fig. 7B, right panel). The effect of U0126 was specific to mGluR-LTD in Δ RG mice, because this concentration of the drug did not significantly impact mGluR-LTD in wild-type littermates (Fig. 7B, left panel). To determine whether treatment of Δ RG hippocampal slices with U0126 rescued mGluR-LTD back to the same level of control groups (WT + vehicle; WT + U0126) we analyzed the average fEPSP slopes from WT and Δ RG hippocampal slices in the presence of the vehicle or U0126 during the time period of 20 to 50 min after the washout of DHPG. We found that treatment with U0126 returned mGluR-LTD in Δ RG mice back to levels observed in WT mice (Fig. 7C). We then determined whether treatment with DHPG resulted in a further increase in ERK phosphorylation in Δ RG mice. Hippocampal slices were treated with DHPG and area CA1 was isolated. Western blot data showed a significant increase of ERK phosphorylation in slices from Δ RG mice treated with DHPG (Fig. 8A). In addition, Western blot analysis from area CA1 of hippocampal slices collected after the rescue experiment confirmed the reduction of ERK phosphorylation by U0126 (1 μ M) (Fig. 8B). Taken together, these findings are consistent with the idea that the impaired hippocampal mGluR-LTD exhibited by Δ RG mice is due to enhanced MEK–ERK signaling.

Discussion

Our examination of hippocampal synaptic plasticity in the Δ RG mouse model of TSC resulted in several unexpected findings. First, we observed that both E-LTP and L-LTP were unaltered in Δ RG mice (Figs. 3A and B). In contrast, E-LTP-inducing stimulation was shown to produce stable, rapamycin-sensitive, L-LTP in TSC2 heterozygous knockout mice (Ehninger et al., 2008). It appears that in the complete absence of one allele, as in the case of TSC2 heterozygous knockout

mice, the impact on mTORC1 signaling is more robust and broader than in the case of having specific mutations in the TSC2-GAP domain as is present in the Δ RG mice. Indeed, we observed that mTORC1 signaling was not significantly altered in the Δ RG mice (Fig. 4), whereas mTORC1 signaling in both TSC1^{+/-} cKO and TSC2^{-/-} cKO mice were enhanced as shown by increase phosphorylation of S6K1 (Supplementary Fig. 1). The latter finding is consistent with recent studies where the hippocampal deletion of the *Tsc1* gene resulted in enhanced mTORC1 signaling (Bateup et al., 2011). The second unexpected finding was that mGluR-LTD was impaired in the Δ RG mice (Fig. 3D). Moreover, the Δ RG mice exhibited normal NMDAR-LTD in (Fig. 3C), similar to recent findings in mice with virally-mediated deletion of the *Tsc1* gene in the hippocampus (Bateup et al., 2011). Thus, disruption of TSC2-GAP function, either by GAP mutations or decreasing TSC1/2 heterodimer stability compromising TSC2-GAP activity, interferes with distinct molecular mechanisms required for the expression of mGluR-LTD but not NMDAR-LTD.

mGluR-LTD in both TSC1^{+/-} cKO and TSC2^{-/-} cKO mice was impaired at the same level as it was in Δ RG mice (Fig. 4C). Our findings with TSC1^{+/-} cKO mice (Fig. 4A) confirm recent studies showing that the loss of *Tsc1* impairs hippocampal mGluR-LTD (Bateup et al., 2011). The impaired mGluR-LTD in Δ RG mice was unexpected because mGluR-LTD, ERK phosphorylation, and mTORC1 signaling are enhanced in FXS model mice that lack FMRP, a translation suppressor (Hou et al., 2006; Sharma et al., 2010). It is possible that there are different subcellular pools of ERK that are activated in Δ RG mice and FXS mice that results in the phosphorylation of dissimilar ERK substrates that impact mGluR-LTD differently. Interestingly, the mGluR-LTD phenotype in the Δ RG mouse model of TSC differs from FXS model mice lacking FMRP, but more closely approximates that observed in transgenic mice overexpressing FMRP, which exhibit completely abolished mGluR-LTD (Hou et al., 2006). Thus, Δ RG mice and FXS mice are examples of two types of improper activation of ERK and mTORC1 signaling in the brain. In Δ RG mice, robust enhancement of ERK signaling results in impaired mGluR-LTD, whereas modest activation of ERK and mTORC1 signaling in FXS model mice results in enhanced mGluR-LTD (Hou et al., 2006; Sharma et al., 2010).




Fig. 7. Impaired mGluR-LTD in Δ RG mice is rescued by inhibition of MEK-ERK signaling. (A) Incubation of wild-type (WT) hippocampal slices for 30 min with 100 nM U0126 did not alter, whereas incubation with 1 μ M and 5 μ M U0126 significantly decreased ERK phosphorylation ($n = 6$ mice; 2–3 slices per treatment. *** $p < 0.0001$, one-way ANOVA analysis followed by Dunnett's test [control vs. 100 nM, $p > 0.05$; control vs. 1 μ M, ** $p < 0.001$; control vs. 5 μ M, *** $p < 0.0001$]). (B) Left panel: Top, representative fEPSPs in slices from WT mice before and after treatment with DHPG (50 μ M, 10 min) to induce mGluR-LTD in the presence of either vehicle (DMSO) or U0126 (1 μ M). Calibration: 5 mV, 5 ms. Bottom, mGluR-LTD was induced by DHPG application in the presence of either vehicle or 1 μ M U0126 in WT mice (WT + vehicle, $n = 14$; WT + U0126, $n = 14$; 1–2 slices/mouse per drug treatment. $p > 0.05$, ANOVA). Right panel: top, representative fEPSPs in slices from Δ RG mice before and after treatment with DHPG (50 μ M, 10 min) to induce mGluR-LTD in the presence of either vehicle or U0126 (1 μ M). Bottom, mGluR-LTD was induced by DHPG application in the presence of 1 μ M U0126, but not vehicle, in Δ RG mice (Δ RG + vehicle, $n = 12$; Δ RG + U0126, $n = 13$; 1–2 slices/mouse per drug treatment. *** $p < 0.0001$, ANOVA). The vehicle and U0126 were present before, during and after DHPG application. (C) Left panel: bar graph depicting average fEPSP slope 20 to 50 min after the washout of DHPG in the presence of either vehicle or U0126 (WT + vehicle, $n = 14$; WT + U0126, $n = 14$; Δ RG + vehicle, $n = 12$; Δ RG + U0126, $n = 13$; ** $p < 0.01$, one-way ANOVA; *** $p < 0.05$, Student's t -test compared with Δ RG + vehicle for the given time period]).

Although upregulated mTORC1 signaling has been reported in other mouse models of TSC and FXS (Bateup et al., 2011; Ehninger et al., 2008; Sharma et al., 2010), the mutation in the TSC2-GAP domain in the Δ RG mice appears to recruit an mTORC1-independent mechanism in the hippocampus, the third unexpected finding in our studies. Normally, TSC2 negatively regulates Rheb, which is immediately upstream of mTORC1 (Tee et al., 2003). Active, GTP-bound Rheb also has been shown to negatively regulate Ras/B-Raf/C-Raf/MEK signaling by disrupting B-Raf/C-Raf heterodimerization (Im et al., 2002; Karbowniczek et al., 2006). B-Raf has a high basal kinase activity toward MEK1/2, and is now available to participate in the activation Rap1/Epac/B-Raf signaling pathway (Moodie et al., 1994; Papin et al., 1996; Papin et al., 1998; Reuter et al., 1995; Wang et al., 2006), which is then a potential mechanism for the upregulated

ERK phosphorylation and S6 235/236 phosphorylation observed in the Δ RG mice (Figs. 5A and C). In fact, the impaired mGluR-LTD observed in Δ RG mice was rescued by the MEK inhibitor U0126, supporting the idea that elevated MEK-ERK signaling contributes to synaptic abnormalities in these mice (Fig. 7B). Moreover, the enhanced basal phosphorylation of ERK in Δ RG mice is further increased by DHPG treatment (Fig. 8A). In contrast, conditional deletion of *Tsc1* and *Tsc2* genes in the forebrain did not result in upregulated ERK phosphorylation (Fig. 6). Thus, it is possible that synaptic and behavioral phenotypes in mice with conditional deletions of *Tsc1* and *Tsc2* might be due to exaggerated mTORC1 signaling (Supplementary Fig. 1B) (Bateup et al., 2011; Ehninger et al., 2008) in contrast to the Δ RG mice where the phenotypes are due to exaggerated ERK signaling.




Fig. 8. Biochemical analysis of MEK/ERK signaling inhibition during mGluR-LTD induction in Δ RG mice. (A) ERK phosphorylation is further increased in area CA1 of hippocampal slices from Δ RG mice after treatment with DHPG (50 μ M, 10 min) compared to hippocampal slices from wild-type (WT) mice treated with DHPG ($n = 3-4$ slices per treatment. *** $p < 0.0001$, one-way ANOVA analysis. Student's t -test [WT + vehicle vs. Δ RG + vehicle, * $p < 0.05$; WT + DHPG vs. Δ RG + DHPG, * $p < 0.05$; Δ RG + vehicle vs. Δ RG + DHPG, ** $p < 0.01$; WT + vehicle vs. WT + DHPG, *** $p < 0.0001$]. (B) ERK phosphorylation is decreased in area CA1 from both WT and Δ RG hippocampal slices treated with U0126 (1 μ M) after mGluR-LTD compared to control DMSO ($n = 6-8$ slices per treatment. ** $p < 0.01$, one-way ANOVA analysis followed by Bonferroni's test [Δ RG + vehicle vs. WT + U0126, * $p < 0.05$; Δ RG + vehicle vs. Δ RG + U0126, * $p < 0.05$]).

An additional potential mechanism for the elevated ERK phosphorylation we observed in the Δ RG mice is altered activity of the striatal-enriched protein tyrosine phosphatase (STEP). STEP is a phosphatase shown to regulate synaptic function by modulating NMDA and AMPA receptor trafficking, as well as ERK phosphorylation and nuclear translocation (Braithwaite et al., 2006; Paul et al., 2003; Snyder et al., 2005). In addition, studies have shown that STEP translocation is triggered by activation of group I mGluRs and subsequent activation of the ERK, PI3K and mTORC1 pathways (Zhang et al., 2008). It remains to be determined whether dysregulation of STEP is involved in the elevated ERK phosphorylation observed in the Δ RG mice.

Importantly, in accordance with our findings, analyses of brain lesions and tumors associated with TSC have shown aberrantly activated ERK that is correlated with increased phosphorylation of ribosomal protein S6 (Jozwiak et al., 2008; Ma et al., 2005; Ma et al., 2007). Thus, simultaneous treatment with inhibitors of both mTORC1 and ERK signaling pathways could be an effective treatment for TSC patients. Future studies will be required to delineate the molecular mechanism resulting in altered TSC1/2-ERK signaling and whether it is involved in any cognitive and behavioral abnormalities displayed by the Δ RG mice.

Conclusions

Our studies herein show that disruptive mutations of the GAP domain of TSC2 impair the expression of mGluR-LTD in Δ RG mice, without affecting NMDAR-dependent LTD. Moreover, rescue experiments with the MEK inhibitor U0126 supports the idea that mutations in the TSC2-GAP domain in the Δ RG mice recruit an ERK-dependent and mTORC1-independent mechanism, resulting in impaired mGluR-LTD. In contrast, MEK-ERK signaling appears to be normal but mTORC1 signaling is elevated in mice with conditional deletion of *Tsc1* and *Tsc2* genes, suggesting that impaired mGluR-LTD in these mice is due to exaggerated mTORC1 signaling. Consequently, Δ RG mice is a mouse model of TSC that can be used to study the

role of both TSC2-GAP domain and TSC1/2-ERK signaling in abnormal synaptic plasticity associated with TSC.

Supplementary materials related to this article can be found online at doi:10.1016/j.nbd.2011.12.028.

Acknowledgments

This work was supported by the National Institutes of Health grants NS034007 and NS047384 (E.K.), and MH085489 (I.C.T.).

References

- Banko, J.L., et al., 2006. Regulation of eukaryotic initiation factor 4E by converging signaling pathways during metabotropic glutamate receptor-dependent long-term depression. *J. Neurosci.* 26, 2167–2173.
- Bateup, H.S., et al., 2011. Loss of Tsc1 in vivo impairs hippocampal mGluR-LTD and increases excitatory synaptic function. *J. Neurosci.* 31, 8862–8869.
- Bhatia, B., et al., 2009. Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: separate regulation of mammalian target of rapamycin activity and p27 Kip1 localization. *Cancer Res.* 69, 7224–7234.
- Boer, K., et al., 2008. Cellular localization of metabotropic glutamate receptors in cortical tubers and subependymal giant cell tumors of tuberous sclerosis complex. *Neuroscience* 156, 203–215.
- Braithwaite, S.P., et al., 2006. Synaptic plasticity: one STEP at a time. *Trends Neurosci.* 29, 452–458.
- Cai, S.L., et al., 2006. Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. *J. Cell Biol.* 173, 279–289.
- Camposano, S.E., et al., 2009. Distinct clinical characteristics of tuberous sclerosis complex patients with no mutation identified. *Ann. Hum. Genet.* 73, 141–146.
- Cheadle, J.P., et al., 2000. Molecular genetic advances in tuberous sclerosis. *Hum. Genet.* 107, 97–114.
- Chévere-Torres, I., et al., 2011. Impaired social interactions and motor learning in tuberous sclerosis complex model mice expressing a dominant/negative form of tuber. *Neurobiol. Dis.*, in press.
- Dabora, S.L., et al., 2001. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. *Am. J. Hum. Genet.* 68, 64–80.
- DiMario Jr., F.J., 2004. Brain abnormalities in tuberous sclerosis complex. *J. Child Neurol.* 19, 650–657.
- Ehninger, D., Silva, A.J., 2010. Increased levels of anxiety-related behaviors in a Tsc2 dominant negative transgenic mouse model of tuberous sclerosis. *Behav. Genet.* 40, 525–535.
- Ehninger, D., et al., 2008. Reversal of learning deficits in a Tsc2^{+/−} mouse model of tuberous sclerosis. *Nat. Med.* 14, 843–848.
- Favata, M.F., et al., 1998. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. *J. Biol. Chem.* 273, 18623–18632.

- Gallagher, S.M., et al., 2004. Extracellular signal-regulated protein kinase activation is required for metabotropic glutamate receptor-dependent long-term depression in hippocampal area CA1. *J. Neurosci.* 24, 4859–4864.
- Govindarajan, B., et al., 2005. Transgenic expression of dominant negative tuberlin through a strong constitutive promoter results in a tissue-specific tuberous sclerosis phenotype in the skin and brain. *J. Biol. Chem.* 280, 5870–5874.
- Hernandez, O., et al., 2007. Generation of a conditional disruption of the Tsc2 gene. *Genesis* 45, 101–106.
- Hou, L., Klann, E., 2004. Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression. *J. Neurosci.* 24, 6352–6361.
- Hou, L., et al., 2006. Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. *Neuron* 51, 441–454.
- Huber, K.M., et al., 2002. Altered synaptic plasticity in a mouse model of fragile X mental retardation. *Proc. Natl. Acad. Sci. U. S. A.* 99, 7746–7750.
- Im, E., et al., 2002. Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells. *Oncogene* 21, 6356–6365.
- Jansen, A.C., et al., 2006. Unusually mild tuberous sclerosis phenotype is associated with TSC2 R905Q mutation. *Ann. Neurol.* 60, 528–539.
- Jones, A.C., et al., 1997. Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis. *Hum. Mol. Genet.* 6, 2155–2161.
- Jozwiak, J., 2006. Hamartin and tuberlin: working together for tumour suppression. *Int. J. Cancer* 118, 1–5.
- Jozwiak, J., et al., 2005. Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway. *Neuromolecular Med.* 7, 287–296.
- Jozwiak, J., et al., 2008. Possible mechanisms of disease development in tuberous sclerosis. *Lancet Oncol.* 9, 73–79.
- Karbowiczek, M., et al., 2006. Rheb inhibits C-raf activity and B-raf/C-raf heterodimerization. *J. Biol. Chem.* 281, 25447–25456.
- Krymskaya, V.P., 2003. Tumour suppressors hamartin and tuberlin: intracellular signaling. *Cell. Signal.* 15, 729–739.
- Kwiatkowski, D.J., 2003. Tuberous sclerosis: from tubers to mTOR. *Ann. Hum. Genet.* 67, 87–96.
- Kwiatkowski, D.J., et al., 2002. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. *Hum. Mol. Genet.* 11, 525–534.
- Ma, L., et al., 2005. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. *Cell* 121, 179–193.
- Ma, L., et al., 2007. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. *Cancer Res.* 67, 7106–7112.
- Maheshwar, M.M., et al., 1997. The GAP-related domain of tuberlin, the product of the TSC2 gene, is a target for missense mutations in tuberous sclerosis. *Hum. Mol. Genet.* 6, 1991–1996.
- Moodie, S.A., et al., 1994. Association of MEK1 with p21ras.GMPPNP is dependent on B-Raf. *Mol. Cell. Biol.* 14, 7153–7162.
- Orlova, K.A., Crino, P.B., 2010. The tuberous sclerosis complex. *Ann. N. Y. Acad. Sci.* 1184, 87–105.
- Osterweil, E.K., et al., 2010. Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. *J. Neurosci.* 30, 15616–15627.
- Papin, C., et al., 1996. Identification of signalling proteins interacting with B-Raf in the yeast two-hybrid system. *Oncogene* 12, 2213–2221.
- Papin, C., et al., 1998. Modulation of kinase activity and oncogenic properties by alternative splicing reveals a novel regulatory mechanism for B-Raf. *J. Biol. Chem.* 273, 24939–24947.
- Pasumarthi, K.B., et al., 2000. Enhanced cardiomyocyte DNA synthesis during myocardial hypertrophy in mice expressing a modified TSC2 transgene. *Circ. Res.* 86, 1069–1077.
- Paul, S., et al., 2003. NMDA-mediated activation of the tyrosine phosphatase STEP regulates the duration of ERK signaling. *Nat. Neurosci.* 6, 34–42.
- Pende, M., et al., 2004. S6K1(–/–)/S6K2(–/–) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. *Mol. Cell. Biol.* 24, 3112–3124.
- Reuter, C.W., et al., 1995. Biochemical analysis of MEK activation in NIH3T3 fibroblasts. Identification of B-Raf and other activators. *J. Biol. Chem.* 270, 7644–7655.
- Richter, J.D., Klann, E., 2009. Making synaptic plasticity and memory last: mechanisms of translational regulation. *Genes Dev.* 23, 1–11.
- Ronesi, J.A., Huber, K.M., 2008. Metabotropic glutamate receptors and fragile x mental retardation protein: partners in translational regulation at the synapse. *Sci. Signal.* 1, pe6.
- Roux, P.P., et al., 2004. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. *Proc. Natl. Acad. Sci. U. S. A.* 101, 13489–13494.
- Sambucetti, L.C., et al., 1989. NF-kappa B activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation. *EMBO J.* 8, 4251–4258.
- Sharma, A., et al., 2010. Dysregulation of mTOR signaling in fragile X syndrome. *J. Neurosci.* 30, 694–702.
- Snyder, E.M., et al., 2005. Regulation of NMDA receptor trafficking by amyloid-beta. *Nat. Neurosci.* 8, 1051–1058.
- Tavazoie, S.F., et al., 2005. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. *Nat. Neurosci.* 8, 1727–1734.
- Tee, A.R., et al., 2003. Tuberous sclerosis complex gene products, Tuberlin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. *Curr. Biol.* 13, 1259–1268.
- Uhlmann, E.J., et al., 2004. Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation. *Glia* 47, 180–188.
- Wang, Z., et al., 2006. Rap1-mediated activation of extracellular signal-regulated kinases by cyclic AMP is dependent on the mode of Rap1 activation. *Mol. Cell. Biol.* 26, 2130–2145.
- Wang, Y., et al., 2007. Neocortical hyperexcitability in a human case of tuberous sclerosis complex and mice lacking neuronal expression of TSC1. *Ann. Neurol.* 61, 139–152.
- Yang, Q., et al., 2006. TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity. *Proc. Natl. Acad. Sci. U. S. A.* 103, 6811–6816.
- Zhang, Y., et al., 2003. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. *Nat. Cell Biol.* 5, 578–581.
- Zhang, Y., et al., 2008. The tyrosine phosphatase STEP mediates AMPA receptor endocytosis after metabotropic glutamate receptor stimulation. *J. Neurosci.* 28, 10561–10566.

630

631